San Francisco, CA and London, UK; 11 April 2007. Already, Dr. Reddy’s Laboratories has broken the $1bn annual revenue mark for the first time, due to vigorous expansion by aacquisition and organic growth. By 2010, Dr. Reddy’s will generate over $3bn in annual revenue, with strong double-digit growth. Importantly, that company is now seriously challenging Indian leader Ranbaxy. These are some of the findings from the “Dr. Reddy’s Laboratories 2007-2012” report, published by the business information company visiongain.
Report author Dr Gordon Low said: "With spectacular sales growth so far in the 2006-2007 fiscal year, visiongain predicts that Dr. Reddy’s will raise its profile even higher in the global pharmaceutical sector. Growth will be particularly evident in generic drugs and contract services. In particular, there will be significant developments in NCE development and international business, including a good chance of Dr. Reddy’s achieving success with an original molecule by early next decade.” Stakeholders in niche pharmaceutical companies therefore cannot afford to ignore developments in Dr. Reddy’s Laboratories.
The purpose of this visiongain report is to examine the commercial prospects for Dr. Reddy’s Laboratories in the global healthcare market. Dr. Reddy’s is already competing well there, especially in key generic drug market segments and developing geographical markets. Its profile as a generics and specialist pharmaceutical company will continue to rise. Dr. Reddy’s Laboratories 2007-2012, critically examines that company through comprehensive research, market forecasting and qualitative analyses.
ENDS
Notes for editors:
To receive your complimentary overview of this report please send an email to Sara Peerun sara.peerun@
Background:
Visiongain is one of the fastest growing and most innovative independent media companies in Europe today. Based in London, UK, visiongain produce a host of business-2-business conferences, newsletters, management reports and E-Zines focusing on the Financial markets, the Pharmaceutical, Telecoms industries and the Defence sector.
